ImmunityBio (IBRX) Accounts Payables (2014 - 2026)
ImmunityBio (IBRX) posted quarterly Accounts Payables of $500000.0 for Q1 2026, up 150.0% year-over-year from $200000.0 in Q1 2025, and down 92.83% quarter-over-quarter from $7.0 million in Q4 2025.
ImmunityBio (IBRX) Accounts Payables (2014 - 2026) Analysis & Trends
ImmunityBio (IBRX) has reported Accounts Payables for 13 consecutive years, with $500000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Accounts Payables rose 150.0% year-over-year to $500000.0; the TTM figure through Mar 2026 stood at $500000.0 (up 150.0% YoY), while the FY2025 annual figure was $7.0 million, up 3933.53% from the prior year.
- Accounts Payables fell to $500000.0 in Q1 2026 per IBRX's latest filing, from $7.0 million in the prior quarter.
- Across five years, Accounts Payables topped out at $33.6 million in Q1 2023 and bottomed at $37000.0 in Q2 2023.
- Historically, Accounts Payables has averaged $5.7 million across 5 years, with a median of $267500.0 in 2024.
- Annual changes were most pronounced in 2023 — Accounts Payables slumped 99.8% — and 2025, when it surged 3933.53%.
- ImmunityBio's Accounts Payables stood at $986000.0 in 2022, then tumbled by 86.21% to $136000.0 in 2023, then rose by 27.21% to $173000.0 in 2024, then soared by 3933.53% to $7.0 million in 2025, then tumbled by 92.83% to $500000.0 in 2026.
- Business Quant data shows IBRX's Accounts Payables at $500000.0 in Q1 2026, $7.0 million in Q4 2025, and $300000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Accounts Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 429.50 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.16 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.52 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 88.42 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 470.30 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 3.05 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 35.57 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 108.02 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 428.93 Mn |
| 10 | ImmunityBio | 7.97 Bn | 7.62 Bn | 50.94 Mn | 12.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 12.00 Mn |
| Mar 31, 2026 | 500,000.00 |
| Dec 31, 2025 | 6.98 Mn |
| Sep 30, 2025 | 300,000.00 |
| Jun 30, 2025 | 112,000.00 |
| Mar 31, 2025 | 200,000.00 |
| Dec 31, 2024 | 173,000.00 |
| Sep 30, 2024 | 235,000.00 |
| Mar 31, 2024 | 113,000.00 |
| Dec 31, 2023 | 136,000.00 |
| Sep 30, 2023 | 200,000.00 |
| Jun 30, 2023 | 37,000.00 |
| Mar 31, 2023 | 33.57 Mn |
| Dec 31, 2022 | 986,000.00 |
| Sep 30, 2022 | 20.24 Mn |
| Jun 30, 2022 | 18.05 Mn |
| Mar 31, 2022 | 9.83 Mn |
| Dec 31, 2021 | 11.42 Mn |
| Sep 30, 2021 | 15.12 Mn |
| Jun 30, 2021 | 19.15 Mn |